key: cord-0774161-h8z7zqg9
authors: Picchi, Giovanna; Di Norcia, Monica; Cofini, Vincenza; Sinatti, Gaia; Cosimini, Benedetta; Vertolli, Paola; Tonello, Franco; Carucci, Anna Cecilia; Necozione, Stefano; Balsano, Clara; Grimaldi, Alessandro
title: Laboratory parameters related to severe disease and death in SARS‐CoV‐2 pneumonia: Retrospective analysis
date: 2021-07-08
journal: J Med Virol
DOI: 10.1002/jmv.27141
sha: c180ee4d3195206c8c1b49ecb40b80026e68c045
doc_id: 774161
cord_uid: h8z7zqg9

The clinical evolution of coronavirus disease 2019 (COVID‐19) is highly variable and hospitalized patients can rapidly develop conditions requiring oxygen support, intensive care unit (ICU) or high dependency unit (HDU) care. Early identification of high‐risk patients is mandatory. We retrospectively collected the medical history, symptoms, radiological, and laboratory findings of COVID‐19 patients hospitalized between February and April 2020. Laboratory data were collected at the first, last, and middle times of hospitalization. We used arterial oxygen partial pressure and fractional inspired oxygen ratio (P/F) to evaluate respiratory status. Outcomes considered were death and ICU/HDU admission. We used the χ (2) or Fisher's exact test to examine differences between categorical variables. Continuous variables were analyzed using the Wilcoxon matched pairs signed‐ranks test and Mann–Whitney test sample test. Of 71 patients admitted, 92% had interstitial pneumonia, and 17% an unfavorable outcome. Negative predictors were age, cerebrovascular disease, obesity, and chronic obstructive pulmonary disease. Baseline P/F was strongly associated with all outcomes. Markers linked to immunological dysregulation like elevated neutrophil‐to‐lymphocyte ratio exhibited prognostic significance over time. A validated prognostic score comprehensive of all these conditions for early staging and management of COVID‐19 patients is urgently needed. Further studies are desirable to evaluate whether laboratory tests can target early treatment in high‐risk patients.

Coronavirus disease 2019 (COVID- 19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified in patients presenting with viral pneumonia in Wuhan, China, in December 2019. Since then, COVID-19 has rapidly spread to the rest of the world causing a pandemic. To date, it has affected more than one hundred million patients globally, with over 2.5 million deaths. 1 The understanding of COVID-19 is evolving.

It affects patients of all ages, causing mainly respiratory symptoms. worse prognosis were male sex, age over 65 years, hypertension, diabetes mellitus, obesity, cardiovascular disease, chronic obstructive pulmonary disease (COPD), malignancy. [2] [3] [4] [5] [6] Clinical features at presentation such as elevated body temperature and peripheral oxygen saturation <92% can also predict a poor prognosis. 7 Many laboratory findings were investigated in COVID-19, including hematological, coagulative, inflammatory, and cardiovascular ones. Among these, low lymphocyte (LYM) count, high neutrophilsto-lymphocytes ratio (NLR), low platelets, elevated D-dimer, C-reactive protein (CRP), and interleukin-6 showed different degrees of prognostic value for poor outcome. [8] [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, in some cases, these prognostic factors showed a cumulative impact. 7 In this study, we retrospectively analyzed the characteristics of 71 COVID-19 hospitalized patients at presentation, to identify patients' features associated with death and severe disease. A specific analysis was addressed to laboratory data and their potential prognostic value over time.

This was a retrospective study on symptomatic patients with admitted to the Infectious disease ward from February, 27 to April, 23 2020, in San Salvatore Hospital of L'Aquila, Italy. Patients were consecutively enrolled. SARS-COV-2 was detected by a reverse-transcription polymerase chain reaction (RT-PCR) on a nasopharyngeal swab, performed at the Clinical Analysis Laboratory of Santo Spirito Hospital in Pescara or the Experimental Zooprophylactic Institute of Abruzzo and Molise "G. Caporale", according to the epidemic period.

The following data were collected: demographic information, medical history, symptoms, radiological and laboratory findings, therapies, complications, and death.

From past medical history, we focused on major comorbidities such as hypertension, cardiovascular disease, diabetes, respiratory conditions such as chronic obstructive pulmonary disease, asthma, cerebrovascular disease, chronic kidney disease, liver disease, cancer or previous solid organ transplantation. All recent symptoms reported by the patients were reported. All patients underwent a chest CT scan or X-ray at presentation.

Laboratory findings were collected at first, middle, and last times (T0, T1, and T2, respectively) of hospital stay with a focus on the complete blood count, levels of lactate dehydrogenase (LDH), ferritin, CRP, D-dimer, fibrinogen, international normalized ratio (INR), liver enzymes and blood gas analysis. We used the ratio between arterial oxygen partial pressure and fractional inspired oxygen (P/F) as oxygenation index to evaluate the levels of respiratory failure, considering that a proportion of patients were in oxygen support from the very beginning of observation.

According to this, respiratory failure was categorized as follows: mild with P/F between 200 and 300, moderate with P/F between 100 and 200, severe with P/F < 100. Data about medical therapy were recorded including treatment with antiviral therapy, systemic corticosteroids, antibiotics, heparin and tocilizumab, duration of therapy, and adverse effects. Patients were classified according to World Health Organization (WHO) guidance and National Institute of Health (NIH) guidelines 17,18 as mild illness (mild clinical symptoms without pneumonia manifestations in imaging), moderate illness (having symptoms and pneumonia manifestation in imaging, with no requirement for supplemental oxygen), severe illness (having radiographic evidence of pneumonia or need for supplemental oxygen) and critical illness (with acute respiratory distress syndrome [ARDS], sepsis, or multiorgan failure).

Descriptive statistics were calculated for all variables in the study, reporting mean and standard deviation (ds) or median and interquartile range (IQR) for numeric variables, as well as frequencies for categorical variables. We used the χ 2 or Fisher's exact test to examine the differences between categorical variables. Continuous variables were analyzed using the Mann-Whitney test for two independent groups. The Wilcoxon matched-pairs signed-ranks test was run to compare laboratory data at baseline and discharge.

All data regarding patients' characteristics at baseline were analysed by the following two outcomes: death and admission in a high dependency unit (HDU) or ICU. We performed a subanalysis of this last outcome considering separately patients in HDU and ICU for laboratory parameters.

All analyses were performed with STATA software setting α = 0.05.

Data from about 71 patients with symptomatic SARS-CoV-2 infection were collected and analysed. All patients were Caucasian, with ages ranging from 24 to 93 (median age 60 years), prevalently males (65%). Nine patients were health-care workers (13%) with a history of exposure to the virus in the work setting, and six patients (8%)

were residential care hosts.

The most common comorbidities were hypertension (51%) and cardiovascular disease (24%). A third of the population was overweight or obese. Median time to admission after presentation was 8 days. The main symptoms reported at admission were fever (90%), cough (61%), and dyspnoea (39%). Respiratory failure (P/F < 300) at admission was observed in 48% of patients, with 20% and 6% overall in the moderate and severe degree group, respectively. Median SpO 2 at admission was 95% (range 85-100) and 21 (30%) were in oxygen therapy. Of 50 patients in an ambient room, 52% had a SpO 2 ≤ 95%. A radiological diagnosis of pneumonia by Chest-CT or X-ray was confirmed in 65 patients (91.5%). Of 61 patients who underwent chest CT-Scan, 98.4% had bilateral and diffuse ground-glass opacities. 

This was a retrospective study in 71 patients hospitalized for symptomatic SARS-CoV-2 infection whose data about comorbidities, clinical and laboratory findings were analysed by two outcomes:

death and admission of HDU or ICU.

The median age of this male-dominated population was 60 years. A third of the population was overweight or obese. Hypertension was the most common comorbidity (51%), and high levels of cardiovascular and respiratory disease were also observed. The majority of patients were hospitalized with fever and respiratory symptoms, and with a high prevalence of interstitial pneumonia. This is congruent with the median time to admission after presentation of 8 days: it corresponds to the "pulmonary phase" of COVID-19. 20 It has to be noticed that only 61% of patients presented with cough, besides 91% with radiologically confirmed pneumonia. This inconsistency between the severity of radiological pattern and mild clinical manifestation has largely been observed before. 21 Moreover, 48% had a degree of hypoxemia, 39% of patients complained of shortness of breath at baseline and 30% were already in oxygen support from Emergency Department, because of low peripheral oxygen saturation values. Those discrepancies probably reflect the contrast between preserved oxygen saturation and arterial hypoxemia ("ventilationperfusion mismatch") previously described in SARS-CoV-2 pneumonia patients. 22 During the hospital stay, defervescence was observed in a median of 12 days after the onset. A high percentage (62%) of patients developed PICCHI ET AL. respiratory failure and a worse respiratory performance was again observed at a median time from onset of 12 days. Overall, 9 patients (12.6%) were admitted to ICU or HDU with a median time of 2 days after hospitalization and 10 days after onset, reflecting the timing of respiratory dysfunction observed before in SARS-CoV-2-infection. 21 Comprehensively, the timeline observed seems to confirm the 10th-12th day of disease as the "key moment" in COVID-19 evolution.

Five patients (7%) were admitted to HDU and survived. Patients admitted to ICU were 4 (5.6%) and one of these died. The prevalence of mortality was 5.6% that is quite lower than that observed in SARS-CoV-2 hospitalized patients in the same epidemic period. 23 29 Obesity resulted as a significant risk factor for disease severity rather than mortality; this is also well-known 29 and not unexpected, considering the repercussions of obesity on pulmonary function.

In this analysis, therapy with Angiotensin II receptor blockers (ARBs) showed a significant association with ICU/HDU admission (p = 0.005). The relationship between this therapy and severe COVID-19 was largely discussed considering the possible role of these drugs in the SARS-CoV-2 life cycle but this correlation was not confirmed in large studies. 30 Statistical analysis showed that the presence of hypoxemia at presentation is significantly related to both outcomes. In particular, having a P/F lower than 200 and 100 resulted in an increased risk of mortality (p = 0.048 and p = 0.014, respectively) and ICU/HDU treatment (P/F < 200 with OR 16.2, p < 0.001, P/F < 100 with p < 0.001). In the last group, also having a P/F < 300 was significantly related to ICU/HDU admission (p = 0.011). Overall, to have a low P/F index at baseline was significantly related with death (p = 0.025), equally to be in oxygen support (p = 0.022). These results are controversial: while it is evident that high levels of hypoxemia are one of the strongest indications for ICU or HDU admission, it is also evident that a more compromised respiratory situation at the time of hospitalization implies a more severe clinical course, a raised probability of high intensity of care and, at least, a higher prevalence of death. For this reason, it is important to emphasize the use of basal hypoxemia as a guiding parameter for the clinician approaching patient management. This is important regardless of respiratory symptoms, which as we said before, are not always congruent with the laboratory data. Anyway, it has to be noted that the presence of dyspnoea at hospitalization was predictive of HDU/ICU admission (p = 0.024). It is important to highlight also that the number of patients who reached the two outcomes is very low.

At admission, the majority of patients had alteration of laboratory parameters. During the first spread of SARS-CoV-2, it was clear that the majority of patients showed alteration in neutrophil and lymphocyte count resulting in a high NLR, and a rise in the level of CPR, D-dimer, fibrinogen, ferritin, and LDH.

The most common alteration found is increased CRP (86.8%).

The majority of patients (79% and 76%, respectively) showed high levels of LDH and ferritin and a very high prevalence of altered values of D-Dimer (66%) and fibrinogen (67%) were observed. We also observed in 59% of patients an NLR over 3.13, which is the value identified, in some studies 31 Statistical analysis showed a significant relationship between many of these alterations at baseline with death and/or HDU/ICU admission.

There were elevated levels of baseline CRP in patients admitted to HDU/ICU (median 10.8 vs. 2.28; p = 0.002), and the significance was partially preserved over time, while no relation was found with death. Also considering ICU and HDU separately, PCR levels were still significantly higher in these groups than in other patients. Correlation between CRP levels and disease severity has already been noticed 32 and the strength of this evidence seems to be high in the meta-analysis study. 29 Elevation of D-dimer was significantly related to both outcomes, and this relation is preserved over time for the death group. The prognostic role of D-dimer, also in his evolution over time, has largely | 5893 been observed before, [12] [13] [14] and D-dimer and seems to be the cardiovascular parameter with the best correlation with ICU treatment and death. 33 This probably reflects the role of coagulation in the physiopathology of severe COVID-19 and supports the use of lowmolecular-weight heparin in these cases. 14 Elevated NLR was significantly related to both death and severity of disease. This relation is preserved over time and with increasing significance, specifically in the HDU group, showing a possible role of this index not only at hospital admission but also during clinical course, and suggesting a link with disease evolution. In this perspective, it is interesting to notice that NLR seems to increase its significance over time and that lymphopenia considered in itself has the same trend. In contrast, Neutrophilia in itself showed inconstant correlations with disease severity and mortality.

Lymphopenia is common in SARS-CoV-2 infection and many studies evidenced its correlation with mortality 8 and severe disease, 9 may be related to an insufficient specific immune response to the virus. 34 Interestingly, a geographic variability in this parameter was observed, with a much higher percentage in patients from Italy if compared with those from some Far East countries. 35 NLR is an index used as a surrogate to assess the extent of systemic inflammation that may have a correlation with severe disease and death. 10, 36 In fact, the "cytokine storm" associated with the dysregulation of inflammatory response seems to play a crucial role in COVID-19 evolution, as observed in other Coronaviruses infections. 37 The NLR cut-off with the best predictive value has not been identified. 38 It is important to highlight that this parameter could be influenced over time by steroidal use. For this reason, also domiciliary usage of steroids should be taken into account. Anyway, none of these patients reported a history of steroidal use. Considering that the beneficial role of steroidal therapy in COVID-19 could be explained by its effects on inflammation, it is also possible to speculate that the use of this drug could be guided by NLR values in an early phase of disease before respiratory failure develops.

Isolated significance was found for high levels of LDH at middle hospitalization and for AST at the end of it for the death group (p = 0.033 and 0.047 respectively), while having low platelets at middle-time of hospitalization was significantly related with ICU/HDU admission (p = .030). A correlation of these alterations with severity of disease and with death has been described in some studies, but their predictive role is controversial 29 so they are probably less specific.

This observational retrospective study conducted during the first epidemic period of the SARS-CoV-2 pandemic highlights the importance of many factors that need to be examined in-depth for future epidemic waves.

Comorbidities, and in particular cerebrovascular and respiratory ones, affect prognosis together with obesity and age. Patients with more than one of these conditions need to be considered as very high-risk patients since the onset of COVID-19 symptoms. Regarding the clinical manifestations, the absence of an evident "shortness of breath" and low levels of peripheral oxygen saturation is probably not accurate enough to define a patient as at low risk for severe-COVID-19. Assessing and quantifying hypoxemia is essential for this purpose. The clinical course of these patients underlines the importance of the 10th-12th day since onset as the key moment in COVID-19 evolution toward a severe or mild disease. For this reason, all SARS-CoV-2 symptomatic patients should be monitored accurately at least until this time.

Data about our population confirmed the importance of some laboratory findings, especially those related to hyperinflammation, as predictors of worse outcomes, both at baseline and over time.

Worldwide the role of those alterations was largely investigated as the prognostic score, combined with high-risk conditions such as comorbidities, age, and sex. It is mandatory to assess in larger studies the weight of these alterations in early staging of COVID-19 patients, creating a validated prognostic score to address those patients with a worse prognostic score with hospitalization and intensive clinical observation. This is essential considering the large numbers of patients simultaneously observed in emergency rooms during the epidemic peaks, and the above-mentioned cruciality of early hospital admission for supportive therapy, to decrease mortality of COVID-19. Lacking a specific antiviral therapy, the potential benefit of an early medical treatment able to modulate inflammatory response in high-risk patients needs to be further investigated. The timing of steroidal therapy remains anyway controversial considering its effect on viral clearance. 26 This study has many limitations. The population size is small and the number of events for all three outcomes is scarce; for this reason, 

The authors declare that there are no conflict of interests. 

China medical treatment expert group for covid-19. clinical characteristics of coronavirus disease 2019 in China

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Prognostic factors for severe coronavirus disease 2019 in Daegu

Laboratory abnormalities in patients with COVID-2019 infection

Hematologic parameters in patients with COVID-19 infection

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a metaanalysis

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study

World Health Organization. Clinical managment of COVID-19

COVID-19) treatment guidelines. National Institutes of Health

TOCIVID-19 -A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol

COVID-19 illness in native and immunosuppressed states: a clinical−therapeutic staging proposal

Acute respiratory failure in COVID-19: is it 'typical' ARDS?

The pathophysiology of 'happy' hypoxemia in COVID-19

International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC)

COVID-19: timing is important

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review

Age and multimorbidity predict death among COVID-19 patients. Results of the SARS-RAS study of the italian society of hypertension

Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy

Prognostic value of vardiovascular biomarkers in COVID-19: a review

The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks

COVID-19 and the clinical hematology laboratory

Neutrophil-to-lymphocyte ratio and outcomes in Louisiana Covid-19 patients

Influenza infection, SARS, MERS and COVID-19: cytokine storm-the common denominator and the lessons to be learned

Predictive values of neutrophil-tolymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis

Laboratory parameters related to severe disease and death in SARS-CoV-2 pneumonia: Retrospective analysis